Literature DB >> 26183298

Strengths and limitations of industry vs. academic randomized controlled trials.

P-F Laterre1, B François2.   

Abstract

Clinical research has evolved substantially over the last two decades, but industry-sponsored research is still substantially superior to academic research in preparing, organizing and monitoring studies. Academics have to realize that conducting clinical research has become a real job with professionalism requirements. The primary objectives of research and development clearly differ between industry and academics. In the first case, new drug development is expected to generate profit, whereas in the latter case, research is aimed at understanding mechanisms of disease, promoting evidence-based medicine, and improving public health and care. However, a large number of clinical studies do not achieve their goals, and the reasons for failure may also differ between sponsored and academic studies. Industry and academics should develop better constructive partnerships and learn from each other. Academics should guide industry in study design and in investigator site selection, and academics should benefit from industry's expertise in improving monitoring and reporting processes. Finally, the existing database from former studies should be opened and shared with academics, to enable the exploration of additional scientific questions and the generation of new hypotheses. The two types of research should not be opposed, but should take the form of a constructive collaboration, increasing the chances of reaching each individual goal.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Academic research; clinical research; controlled trials; data monitoring; industry; study design

Mesh:

Year:  2015        PMID: 26183298     DOI: 10.1016/j.cmi.2015.07.004

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  11 in total

1.  Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis.

Authors:  Jean-Hugues Salmon; Anne-Christine Rat; Isabelle Charlot-Lambrecht; Jean-Paul Eschard; Damien Jolly; Bruno Fautrel
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

2.  Pro-Con Perspectives on Ethics in Surgical Research: Update from the 39th Annual Surgical Infection Society Meeting.

Authors:  Vanessa P Ho; Evelyn I Truong; Saira Nisar; Addison K May; Gregory J Beilman; Donald E Fry; Philip S Barie; Jared M Huston; Jeffrey W Shupp; Fredric M Pieracci
Journal:  Surg Infect (Larchmt)       Date:  2020-05       Impact factor: 2.150

3.  Patch augmentation surgery for rotator cuff repair: the PARCS mixed-methods feasibility study.

Authors:  Jonathan A Cook; Mathew Baldwin; Cushla Cooper; Navraj S Nagra; Joanna C Crocker; Molly Glaze; Gemma Greenall; Amar Rangan; Lucksy Kottam; Jonathan L Rees; Dair Farrar-Hockley; Naomi Merritt; Sally Hopewell; David Beard; Michael Thomas; Melina Dritsaki; Andrew J Carr
Journal:  Health Technol Assess       Date:  2021-02       Impact factor: 4.014

4.  Registered Interventional Clinical Trials for Old Populations With Infectious Diseases on ClinicalTrials.gov: A Cross-Sectional Study.

Authors:  Lingmin Chen; Menghua Wang; Yi Yang; Jing Shen; Yonggang Zhang
Journal:  Front Pharmacol       Date:  2020-06-26       Impact factor: 5.810

5.  Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.

Authors:  David Fraguas; Covadonga M Díaz-Caneja; Laura Pina-Camacho; Daniel Umbricht; Celso Arango
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

Review 6.  Repurposing metformin for the treatment of gastrointestinal cancer.

Authors:  Ademar Dantas Cunha Júnior; Arinilda Campos Bragagnoli; Felipe Osório Costa; José Barreto Campello Carvalheira
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

7.  Registered Clinical Trials Comprising Pregnant Women in China: A Cross-Sectional Study.

Authors:  Yi Zhao; Guiping Du; Xiaofei Luan; Hui Yang; Qiongguang Zhang; Zhengfu Zhang; Subiao Wang
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

8.  Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005.

Authors:  Magdalena Zwierzyna; Mark Davies; Aroon D Hingorani; Jackie Hunter
Journal:  BMJ       Date:  2018-06-06

9.  Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.

Authors:  Yaakov Dickstein; Leonard Leibovici; Dafna Yahav; Noa Eliakim-Raz; George L Daikos; Anna Skiada; Anastasia Antoniadou; Yehuda Carmeli; Amir Nutman; Inbar Levi; Amos Adler; Emanuele Durante-Mangoni; Roberto Andini; Giusi Cavezza; Johan W Mouton; Rixt A Wijma; Ursula Theuretzbacher; Lena E Friberg; Anders N Kristoffersson; Oren Zusman; Fidi Koppel; Yael Dishon Benattar; Sergey Altunin; Mical Paul
Journal:  BMJ Open       Date:  2016-04-20       Impact factor: 2.692

Review 10.  Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP).

Authors:  Edward C Hsiao; Maja Di Rocco; Amanda Cali; Michael Zasloff; Mona Al Mukaddam; Robert J Pignolo; Zvi Grunwald; Coen Netelenbos; Richard Keen; Genevieve Baujat; Matthew A Brown; Tae-Joon Cho; Carmen De Cunto; Patricia Delai; Nobuhiko Haga; Rolf Morhart; Christiaan Scott; Keqin Zhang; Robert J Diecidue; Clive S Friedman; Fredrick S Kaplan; Elisabeth M W Eekhoff
Journal:  Br J Clin Pharmacol       Date:  2018-11-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.